Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.
AIMS: This study is the contribution by the Thoraxcenter, Rotterdam, to the European(32)P Dose Response Trial, a non-randomized multicentre trial to evaluate the safety and efficacy of the radioactive Isostent in patients with single coronary artery disease. METHODS AND RESULTS: The radioactivity of the stent at implantation was 6--12 microCi. All patients received aspirin indefinitely and either ticlopidine or clopidogrel for 3 months. Quantitative coronary angiography measurements of both the stent area and the target lesion (stent area and up to 5 mm proximal and distal to the stent edges) were performed pre- and post-procedure and at the 5-month follow-up. Forty-two radioactive stents were implanted in 40 patients. Treated vessels were the left anterior descending coronary artery (n=20), right coronary artery (n=10) or left circumflex artery (n=10). Eight patients received additional non-radioactive stents. Lesion length measured 10+/-3 mm with a reference diameter of 3.07+/-0.69 mm. Minimal lumen diameter increased from 0.98+/-0.53 mm pre-procedure to 2.29+/-0.52 mm (target lesion) and 2.57+/-0.44 mm (stent area) post-procedure. There was one procedural non-Q wave myocardial infarction, due to transient thrombotic closure. Thirty-six patients returned for angiographical follow-up. Two patients had a total occlusion proximal to the radioactive stent. Of the patent vessels, none had in-stent restenosis. Edge restenosis was observed in 44%, occurring predominantly at the proximal edge. Target lesion revascularization was performed in 10 patients and target vessel revascularization in one patient. No additional clinical end-points occurred during follow-up. The minimal lumen diameter at follow-up averaged 1.66+/-0.71 mm (target lesion) and 2.12+/-0.72 (stent area); therefore late loss was 0.63+/-0.69 (target lesion) and 0.46+/-0.76 (stent area), resulting in a late loss index of 0.65+/-1.15 (target lesion) and 0.30+/-0.53 (stent area). CONCLUSION: These results indicate that the use of radioactive stents is safe and feasible, however, the high incidence of edge restenosis makes this technique currently clinically non-applicable.
|Keywords||*Stents/adverse effects, Adult, Aged, Angioplasty, Transluminal, Percutaneous Coronary/adverse effects/*instrumentation/*methods, Brachytherapy/adverse effects/*instrumentation/*methods, Coronary Angiography, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction/etiology/radiography/*radiotherapy, Phosphorus Radioisotopes/adverse effects/*therapeutic use, Radiation Dosage, Recurrence, Research Support, Non-U.S. Gov't, Risk Factors, Safety, Severity of Illness Index, Treatment Outcome, beta-particles, radioisotope, restenosis, stent|
|Persistent URL||dx.doi.org/10.1053/euhj.2000.2283, hdl.handle.net/1765/12923|
Wardeh, A.J., Knook, A.H.M., Kay, I.P., Sabaté, M., Coen, V.L.M.A., Foley, D.P., … Serruys, P.W.J.C.. (2001). Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.. European Heart Journal, 22(8), 669–675. doi:10.1053/euhj.2000.2283